Spine BioPharma Inc. announced that it has signed an agreement with Ensol BioSciences Inc. to expand the indications (treatment scope) of its therapeutic drug treatment candidate, SB-01 For Injection. The agreement, valued at a total of $155 million, grants Spine BioPharma the exclusive rights to develop and commercialize SB-01 For Injection, for all additional indications beyond spine-related diseases, such as osteoarthritis, fibrotic diseases, and Oncological indications.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,090 KRW | -8.97% |
|
-12.50% | -2.09% |
1st Jan change | Capi. | |
---|---|---|
-2.09% | 3.8Cr | |
+21.59% | 13TCr | |
+24.67% | 12TCr | |
+26.23% | 2.77TCr | |
-18.69% | 2.03TCr | |
-15.59% | 1.68TCr | |
-17.93% | 1.56TCr | |
+13.35% | 1.48TCr | |
-47.70% | 1.46TCr | |
+58.21% | 1.44TCr |
- Stock Market
- Equities
- A140610 Stock
- News Ensol Biosciences Inc.
- Spine BioPharma, Inc. Announces Agreement with Ensol BioSciences, Inc. to Expand Indications for SB-01 For Injection